Biogen
NEWS
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
Biogen’s plan to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease is being met with hope for a needed therapy for a dreaded disease, but also some skepticism regarding its long-term efficacy and, ultimately, potential.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
The pharmaceutical company, Biogen presented further analysis from two phase III trials of the potential new Alzheimer’s drug, aducanumab.
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
JOBS
IN THE PRESS